RxDoctor Payments DataLook up a doctor →

Matthew Janik, MD

Cardiovascular Disease · Wilmington, NCNPI 1619150554

Payments from drug & device makers

$3,957,962in general payments, 2019–2025

Across 853 payments — averaging $4640.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1.1M
  • Eli Lilly$910K
  • Merck$511K
  • Novartis$426K
  • AbbVie$275K
  • Amgen$273K
  • plus $495K from 46 others
$110,320in research payments, 2019–2025

Across 3 payments — averaging $36,773 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$108K
  • Regeneron$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC59$1,066,764
Eli Lilly5$910,329
Merck48$511,224
Novartis59$426,300
AbbVie52$275,247
Amgen22$273,473
Regeneron32$192,955
AstraZeneca41$122,824
American Regent19$89,130
Boehringer Ingelheim36$37,633
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)28$27,389
E.r. Squibb & Sons, L.L.C.78$7,334
BD1$6,883
Esperion Therapeutics, Inc.12$4,485
Novo Nordisk AS156$1,211
Johnson & Johnson61$713
Boehringer Ingelheim Pharma GmbH & Co.kg1$508
Philips North America LLC30$455
Sanofi-aventis U.S. LLC18$341
Boehringer Ingelheim Canada Ltd.ltee3$330
Sanofi US Services Inc.1$293
Boston Scientific10$218
Novo Nordisk9$209
Abiomed2$205
Boehringer Ingelheim France S.a.s.2$173
Pfizer9$136
Chiesi USA, Inc.7$127
Cvrx, Inc.2$114
Lantheus Medical Imaging, Inc.6$103
Abbott5$99
Lundbeck LLC6$86
Inspire Medical Systems, Inc.3$81
Amarin Pharma, Inc.4$74
Actelion Pharmaceuticals US, Inc.2$49
Lexicon Pharmaceuticals, Inc.3$47
Biotronik Inc.2$39
Astellas Pharma US Inc2$38
Cardiovascular Systems Inc.1$35
Bayer2$34
Siemens Medical Solutions USA, Inc.1$32
Braemar Manufacturing, LLC1$29
United Therapeutics Corporation2$29
Edwards Lifesciences1$26
Bridgebio Pharma, Inc.1$26
Atricure, Inc.1$25
Regeneron Healthcare Solutions, Inc.1$19
Kiniksa Pharmaceuticals, Ltd.1$16
Arbor Pharmaceuticals, Inc.1$15
Bardy Diagnostics, Inc.1$15
Aegerion Pharmaceuticals, Inc.1$15
Corvista Health, Inc.1$13
Kowa Pharmaceuticals America, Inc.1$13

How this compares

$3,957,962 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina →

Medicare billing

Part B allowed, 2024
$434,977
Medicare patients
1,508
Services billed
12,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Wilmington

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →